Cargando…
Unsatisfactory quality of E. coli asparaginase biogenerics in India: Implications for clinical outcomes in acute lymphoblastic leukaemia
BACKGROUND: The biotherapeutic asparaginase is a cornerstone of therapy in acute lymphoblastic leukaemia (ALL). With limited access to the original native Escherichia coli-derived asparaginase (EcASNase), a variety of EcASNase biogenerics are used in low-middle-income countries (LMICs). The variable...
Autores principales: | Sidhu, Jasmeet, Gogoi, Manash Pratim, Agarwal, Praveen, Mukherjee, Tathagata, Saha, Debparna, Bose, Priyanka, Roy, Prakriti, Phadke, Yogesh, Sonawane, Bhatu, Paul, Pritha, Saha, Vaskar, Krishnan, Shekhar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7613163/ https://www.ncbi.nlm.nih.gov/pubmed/33939263 http://dx.doi.org/10.1002/pbc.29046 |
Ejemplares similares
-
Activity and toxicity of intramuscular 1000 iu/m(2) polyethylene glycol‐E. coli
L‐asparaginase in the UKALL 2003 and UKALL 2011 clinical trials
por: Sidhu, Jasmeet, et al.
Publicado: (2022) -
Protocol for ICiCLe-ALL-14 (InPOG-ALL-15-01): a prospective, risk stratified, randomised, multicentre, open label, controlled therapeutic trial for newly diagnosed childhood acute lymphoblastic leukaemia in India
por: Das, Nandana, et al.
Publicado: (2022) -
The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis
por: Hu, Xingdi, et al.
Publicado: (2019) -
Comparative treatment costs of risk‐stratified therapy for childhood acute lymphoblastic leukemia in India
por: Mungle, Tushar, et al.
Publicado: (2022) -
Spectrum of respiratory viral infections in children with cancers: Experience from a tertiary cancer centre in Eastern India
por: Bhattacharyya, Arpita, et al.
Publicado: (2016)